Web guides published on October 28, 2026 repeat a message many people taking Ozempic-style drugs have probably seen before: if you plan to get pregnant, the drug should be stopped well ahead of time12. One of the pieces says experts advise stopping one to two months before trying to conceive or starting fertility treatment2. Another says most providers recommend stopping at least one month ahead, and also that current guidelines suggest at least two months1. A third, from a company that sells these drugs, puts the gap at two to three months3.
This article looks at what that advice rests on, where the versions differ, and what is still not known. One point up front: none of the sources Biohack reviewed reports a new decision by a regulator or a medical society. They are summaries of existing labels and earlier studies.
What the advice says
The drugs in question belong to a class known as GLP-1 drugs. They copy a gut hormone that signals fullness, slows how fast the stomach empties and prompts the pancreas to release insulin3. The best-known are semaglutide, sold as Ozempic, Wegovy and Rybelsus, and tirzepatide, sold as Mounjaro32.
The sources agree on the broad point that these drugs are not recommended during pregnancy13. TrimRX writes that the FDA and the drugmakers advise against using them while pregnant3. One of the web guides says Wegovy’s product label states it should not be used during pregnancy1.
Where they part ways is timing:
- At least one month: one guide says this is what most healthcare providers recommend1.
- One to two months: the other guide attributes this to unnamed experts, for both natural attempts and fertility treatment2.
- Two months: both guides say this is what the labels for Ozempic, Wegovy and Rybelsus state for women planning a pregnancy12. One adds that MotherToBaby, a service on medicines in pregnancy, gives the same advice2.
- Two to three months: TrimRX gives this range for semaglutide and tirzepatide3.
- Longer: one guide says a longer break might be advised for people on high doses or preparing for IVF (in vitro fertilization, where eggs are fertilized in a lab)2.
Biohack did not have the drug labels or the MotherToBaby fact sheet itself among its sources, so the two-month figure is reported here as the web guides describe it.
Why the sources say a gap is needed
The reason given is how long the drugs stay in the body. These are weekly, long-acting medicines3. One guide says semaglutide has a half-life of about 7 days, meaning it takes about a week for the amount in the body to fall by half2. The stopping gap is described as a “washout period” that lets the drug clear before a pregnancy begins13.
The second reason is the lack of safety information. Pregnant people are not included in drug trials, so there is no direct trial data on safety in human pregnancy3. In its place are animal studies. TrimRX writes that in pregnant rats, rabbits and monkeys, exposure to these drugs at certain doses was linked to more miscarriages or stillbirths, smaller babies and more birth defects, especially of the skeleton and major blood vessels3. These are animal results and may not carry over to people, as the same source notes3.
Weight loss itself is a concern too. The sources say weight loss is not recommended in pregnancy because it can deprive the developing baby of nutrients13.
What is known in people
Human evidence is thin and mostly observational, meaning researchers looked back at pregnancies rather than running controlled tests. One guide says some research suggests GLP-1 drug use in early pregnancy may be linked to higher risks of miscarriage, malformations, stillbirth and low birth weight1. It also describes one study in which pregnancies exposed to semaglutide had higher rates of early birth, larger-than-expected babies, low blood sugar in newborns and jaundice1. The guide itself says these findings are observational and need more study1. It does not name the studies, their size or who ran them.
There is also a possible upside on the fertility side. The same guide says some research suggests these drugs might improve natural pregnancy rates and menstrual regularity in women with polycystic ovary syndrome (PCOS), a common hormone condition that can affect ovulation1. It stresses that this does not change the advice against use during pregnancy1.
Stopping has effects of its own. One guide says changes in appetite and menstrual cycles can show up within 3 to 5 weeks of stopping semaglutide2. It also says studies link stopping these drugs during pregnancy to more weight gain in pregnancy and weight regain2. Biohack has covered weight regain after these drugs before, in a story on a gut procedure tested after Zepbound.
What this does not show
The advice pieces do not settle how risky these drugs are in early human pregnancy. They also do not explain why the suggested gap ranges from one month to three months. The sources even disagree with themselves at points. One guide’s summary states flatly that semaglutide increases the chance of birth defects in humans, while its main text says the risks to human pregnancy are uncertain and that safety is not definitively established1. Readers should treat the stronger line with caution, since the guide’s own body does not back it with data.
For unplanned pregnancies, the sources say the prescribing doctor should be told right away13. TrimRX goes further and says the drug should be stopped immediately3. One guide also mentions using backup birth control during the stopping period1. Biohack reports these statements as what the sources say, not as advice.
Who is behind the advice
The sources matter here. Two of the three are pages on the same website, brittsamoson.com, published on the same morning under different bylines, with no named medical reviewers and no linked studies12. The third is a blog post from TrimRX, a company that runs medically supervised weight-loss programs using these drugs and invites readers to start treatment3. That is a commercial interest in the topic. Its post was first published in February 2026 and updated in July 20263.
None of these is a primary source such as a drug label, a regulator’s notice or a published study. That is why Biohack labels this an advice summary with no new data.
What to watch next
As use of these drugs spreads, more people taking them reach the point of planning a family, a trend TrimRX also describes3. The questions that would move this story forward are concrete: larger studies of pregnancies exposed to these drugs, any formal statement from a medical society on the right stopping gap, and any change to the drug labels. Biohack will update this thread when one of those arrives.
